"Beyond the Exam Chair" - Future Directions for Glaucoma Care

Glaucoma represents a complex degenerative optic neuropathy that is initially asymptomatic and undetectable until later stages. Historically, glaucoma management has relied on periodic, office-based measurements of intraocular pressure (IOP). While this method guided glaucoma clinical practice for decades, expanding insights into disease pathophysiology are more suggestive of a complex interplay between genetic, physiologic, and systemic factors that extend beyond the ophthalmic exam chair. Emerging technologies and biomedical discoveries are prompting a shift toward a more proactive and comprehensive approach to glaucoma management. Advances in predictive tools and remote monitoring modalities are expanding clinicians' ability to diagnose patients and monitor disease progression more effectively. Polygenic risk scores (PRS) provide a quantitative measure of genetic susceptibility and may help identify high-risk patients before clinical disease develops. When combined with traditional clinical risk factors, PRS may enhance screening strategies and guide treatment intensity. Home tonometry enables continuous measurement of diurnal and nocturnal IOP fluctuations, capturing clinically significant pressure spikes that are frequently missed during routine office visits. Emerging visual field-testing platforms may also enable more frequent and accessible monitoring, further improving the ability to detect early disease progression. There is growing recognition that systemic comorbidities contribute meaningfully to glaucoma pathophysiology. Conditions such as obstructive sleep apnea, systemic hypertension, vascular dysregulation, and pseudoexfoliation syndrome can influence optic nerve perfusion and disease progression. This highlights the importance of evaluating systemic physiologic parameters and considering their contributions to any potential adverse effects on ocular perfusion pressure and optic nerve health. Leveraging this concept, systemic medications are also emerging as potential modifiers of glaucoma risk and progression. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes and weight management, demonstrate anti-inflammatory and neuroprotective properties that may benefit retinal ganglion cells. Conversely, certain antihypertensive medications such as calcium channel blockers may negatively affect retinal perfusion and potentiate vision loss. Together, these developments suggest that glaucoma should be approached as a multifactorial systemic disease rather than solely an ocular condition. Integrating advanced diagnostics, continuous physiologic monitoring, systemic disease management, and emerging therapeutic insights may enable earlier intervention and more individualized care, ultimately reducing the burden of glaucoma-related blindness